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PURPOSE. Vitronectin, a cell adhesion and spreading factor, is suspected to play a role in
the pathogenesis of age-related macular degeneration (AMD), as it is a major component
of AMD-specific extracellular deposits (e.g., soft drusen, subretinal drusenoid deposits).
The present study addressed the impact of AMD-associated non-synonymous variant
rs704 in the vitronectin-encoding gene VTN on vitronectin functionality.
METHODS. Effects of rs704 on vitronectin expression and processing were analyzed by
semi-quantitative sequencing of VTN transcripts from retinal pigment epithelium (RPE)
cells generated from human induced pluripotent stem cells (hiPSCs) and from human
neural retina, as well as by western blot analyses on heterologously expressed vitronectin
isoforms. Binding of vitronectin isoforms to retinal and endothelial cells was analyzed by
western blot. Immunofluorescence staining followed extracellular matrix (ECM) deposi-
tion in cultured RPE cells heterologously expressing the vitronectin isoforms. Adhesion of
fluorescently labeled RPE or endothelial cells in dependence of recombinant vitronectin
or vitronectin-containing ECM was investigated fluorometrically or microscopically. Tube
formation and migration assays addressed effects of vitronectin on angiogenesis-related
processes.
RESULTS. Variant rs704 affected expression, secretion, and processing but not oligomeriza-
tion of vitronectin. Cell binding and influence on RPE-mediated ECM deposition differed
between AMD-risk-associated and non-AMD-risk-associated protein isoforms. Finally,
vitronectin affected adhesion and endothelial tube formation.
CONCLUSIONS. The AMD-risk-associated vitronectin isoform exhibits increased expression
and altered functionality in cellular processes related to the sub-RPE aspects of AMD
pathology. Although further research is required to address the subretinal disease aspects,
this initial study supports an involvement of vitronectin in AMD pathogenesis.
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Age-related macular degeneration (AMD) is a complexdegenerative disorder of the central retina for which
individual genetic variants, as well as environmental and
lifestyle factors, contribute to disease risk.1,2 Currently, the
molecular mechanisms of disease pathology are not fully
understood, although irregularities in processes such as
complement system regulation, extracellular matrix (ECM)
remodeling, lipid metabolism, or vascular modifications are
suspected in the disease pathogenesis.
Vitronectin, a cell adhesion and spreading factor,3
was implicated in AMD in several studies reporting this
protein as a major constituent of drusen4–8 and of subreti-
nal drusenoid deposits.8–10 In addition, the cytoplasm of
drusen-associated retinal pigment epithelial (RPE) cells from
human donors was found to contain elevated amounts of
vitronectin.11 In vitro studies have shown an upregulation of
vitronectin mRNA expression in human induced pluripotent
stem cells (hiPSCs)–RPE cells derived from AMD patients,12
as well as an upregulation of the vitronectin protein
in complement-stimulated, immortalized RPE (ARPE-19)
cells.13
Vitronectin is a secreted glycoprotein circulating in blood
serum but has also been found to be deposited in the ECM of
various tissues.3 In the eye, vitronectin mRNA expression has
been detected in the RPE, in photoreceptors, and in ganglion
cells,4,14 with higher expression levels in the neural retina
compared to the RPE15 (see also the eyeIntegration database,
https://eyeintegration.nei.nih.gov). Conversely, extracellu-
lar labeling of vitronectin protein in the retina is limited
primarily to Bruch’s membrane and the retinal vascula-
ture.14 In particular, the inner collagenous layer of Bruch’s
membrane16 and the basement membrane of endothelial
cells17 contain substantial amounts of vitronectin. The latter
is important for endothelial cell migration and proliferation
(reviewed in Dejana et al.17).
Two vitronectin isoforms are known; one is a single-chain
molecule with a molecular weight of 75 kDa, and the other
is a cleaved form consisting of two chains (65 and 10 kDa)
connected via a disulfide bond.18 Upon binding of specific
ligands or interaction partners, unfolding of monomeric
vitronectin leads to the formation of vitronectin multimers,
stabilized by disulfide and non-covalent bonds.19,20
Copyright 2020 The Authors
iovs.arvojournals.org | ISSN: 1552-5783 1
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloaded from iovs.arvojournals.org on 12/07/2020
Vitronectin Involvement in AMD Pathogenesis IOVS | December 2020 | Vol. 61 | No. 14 | Article 2 | 2
In the largest genome-wide association study known to
date, Fritsche and colleagues21 reported that a genetic vari-
ant, rs704, in the VTN gene was significantly associated
with AMD. Specifically, rs704 is part of a 95% credible set
comprised of 22 genetic variants at the TMEM97–VTN locus
on chromosome 17.21 Although lead variant rs11080055 is
located in intron 1 of the TMEM97 gene, it is still unclear
which genetic variant at this locus may be functionally rele-
vant. This will require a functional dissection of the effects
of the risk-associated variants at this interval, although
some investigations suggest that weighting sequence vari-
ants based on their annotation significantly increases the
power to detect the causative variant of a locus.22,23 Never-
theless, within the described 95% credible set, rs704 is
the only missense and protein-altering variant.21 Further-
more, due to its multifaceted function (reviewed in Leaves-
ley et al.3), vitronectin could affect many processes involved
in AMD pathogenesis, such as angiogenesis or extracellu-
lar matrix integrity (reviewed in Kleinman and Ambati24
and Campochiaro25). Together with the already reported
detection of vitronectin in AMD-related retinal tissues and
deposits, this variant appears to be an excellent candidate
for a targeted functional analysis within this credible set.
The single nucleotide polymorphism rs704, localized in
exon 7 of the VTN gene, leads to an alteration from cytosine
(C) to thymine (T) at nucleotide position 1199, resulting in
an amino acid exchange from threonine to methionine at
amino acid position 400. The replacement of threonine by
methionine was previously shown to decrease the endoge-
nous proteolytic cleavage of vitronectin and thus increase
the presence of the single-chain vitronectin.26
Here, we compared the two vitronectin isoforms
VTN_rs704:T (AMD-risk-associated) and VTN_rs704:C (non-
AMD-risk-associated) in terms of protein expression,
oligomerization, deposition, and functionality in AMD-
related cellular processes. Our data reveal differences of the
two isoforms in expression, cell binding, and their effects on
ECM deposition and endothelial cell migration. Furthermore,
both vitronectin isoforms affected cellular adhesion and
endothelial formation of tubular-like structures. Together,




In accordance with the tenets of the Declaration of Helsinki,
postmortem human donor eyes were collected at the
Ludwig Maximilian University of Munich and the Univer-
sity Hospital Cologne. Each study was approved by the
corresponding local institutional review boards (applica-
tion nos. MUC73416, Munich; 14-247, Cologne). All samples
investigated in this study were approved for research use.
Only clinically asymptomatic retinal samples with no sign
of retinal pathology were included. Generation and anal-
ysis of hiPSC–RPE cells from human donor material have
obtained approval of the ethics review board of the Univer-
sity of Regensburg, Germany (reference no. 12-101-0241 and
amendment to 12-101-0241) and have been performed in
accordance with the ethical standards laid down in the 1964
Declaration of Helsinki and its later amendments. Informed
consent was given by each proband participating in the
study.
Cell Culture
Y79 and WERI-Rb1 cells (American Type Culture Collec-
tion, Manassas, VA, USA) were cultivated in RPMI
medium (Thermo Fisher Scientific, Waltham, MA, USA)
with 10% fetal calf serum (FCS), as well as 100 U/mL
penicillin/streptomycin. ARPE-19 cells (American Type
Culture Collection) were maintained in Dulbecco’s Modi-
fied Eagle Medium/Nutrient Mixture F-12 Ham medium
(DMEM/HamsF12; Sigma-Aldrich, St. Louis, USA) contain-
ing 10% FCS and 100 U/mL penicillin/streptomycin.
Human embryonic kidney cells (HEK293-EBNA; Invitro-
gen, Carlsbad, CA, USA) were maintained in DMEM high-
glucose medium containing 10% FCS, 100 U/mL peni-
cillin/streptomycin, and 500 μg/mL G418. Media and cell
culture supplies were purchased from Life Technologies
(Carlsbad, CA, USA). Human umbilical vein endothelial
cells (HUVECs) were purchased from Life Technologies
(Darmstadt, Germany) and cultured in EGMPlus Endothe-
lial Cell Growth Media with EGMPlus SingleQuots supple-
ments (Lonza Group, Ltd., Basel, Switzerland), but without
gentamycin. HiPSC–RPE cells were generated as described in
Nachtigal et al.27 and Okita et al.28 The hiPSC–RPE cells were
cultured on 12-well or 24-well transwell filter inserts (0.4-
μm pore size; Greiner Bio-One International, Kremsmün-
ster, Austria) coated with Corning Matrigel Growth Factor
Reduced (GFR) Basement Membrane Matrix (Corning, Corn-
ing, NY, USA) in Gibco KnockOut DMEM Medium supplied
with 2-mM L-glutamine, 5% (v/v) KnockOut Serum Replace-
ment, and 0.1-mM Gibco MEM Non-Essential Amino Acids
Solution (all obtained from Life Technologies), as well
as 5-μg/mL gentamycin, 0.1-mM β-mercaptoethanol, and
10-mM nicotinamide (Sigma-Aldrich). Differentiation was
assessed as described previously,29 specifically by investi-
gating RPE-specific gene expression; localization of ZO-1,
BEST-1, ATP1A1, and ATP1B1; and basal and apical secretion
of vascular endothelial growth factor (VEGF), followed by
enzyme-linked immunosorbent assay (R&D Systems, Abing-
don, UK); see also Supplementary Figure S1. A stable high
transepithelial resistance of >150  × cm2 was obtained
after 6 weeks of maturation (233.3 ± 53.2  × cm2). For
propagation, cell lines were grown in a 37°C incubator with
a 5% CO2 environment and subcultured when reaching 90%
confluency for HEK293, HUVECs, and ARPE-19 or a concen-
tration of 4-5 × 105 cells/mL for Y79 and WERI-Rb1. Alter-
ations of these cultivation conditions were used for func-
tional assays and are described in the following subsections.
DNA and RNA Analysis
RNA from hiPSC–RPE or human neural retina was isolated
using the PureLink RNA Micro Kit (Invitrogen), according
to the manufacturer’s protocols. One microgram of total
RNA was transcribed into cDNA using RevertAid M-MuLV
Reverse Transcriptase (Fermentas, St. Leon-Rot, Germany)
and poly(dT) primers according to the manufacturer’s
instructions. Semi-quantitative RT-PCR was performed as
described in Friedrich et al.30 with primers given in Supple-
mentary Table S1. DNA isolation and PCR with genomic DNA
were performed as described in Friedrich et al.31 Primers for
PCR with genomic DNA are shown in Supplementary Table
S1. Sequencing of the RT-PCR products and the genomic
PCR products was performed as described in Friedrich
et al.31 with the primers shown in Supplementary Table S1.
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Antibodies
Applied antibodies, their origin, and dilutions for western
blot or immunocytochemical analyses are given in Supple-
mentary Table S2.
Expression Cloning
After genotyping of ARPE-19 cells that were heterozy-
gous for rs704, the coding sequences for VTN_rs704:C
and VTN_rs704:T were amplified from cDNA of ARPE-19
cells. The fragments were cloned into the BamHI/XhoI site
of the pEXPR-IBA103 vector (IBA Life Sciences, Göttin-
gen, Germany) fusing them to a Twin-Strep-tag (IBA Life
Sciences). Generated vectors allowing expression of Strep-
tagged vitronectin were named pEXPR-IBA103-VTN_rs704:C
and pEXPR-IBA103-VTN_rs704:T. For heterologous expres-
sion of untagged protein, VTN_rs704:C and VTN_rs704:T
were cloned into the NotI/XhoI site of the pcDNA3.1 vector
(Invitrogen). Generated vectors were named pcDNA3.1-
VTN_rs704:C and pcDNA3.1-VTN_rs704:T. To generate a
green fluorescent protein (GFP) expression vector, the GFP
coding sequence was cloned into the BamHI/NotI site of
pcDNA3.1 (the resulting vector was named pcDNA3.1-GFP).
Primer sequences and applied polymerase are given in
Supplementary Table S1.
Heterologous Expression and Purification of
Recombinant Vitronectin Isoforms
To explore the effects of rs704 on vitronectin expres-
sion and secretion, HEK293 and ARPE-19 cells were
co-transfected with pcDNA3.1-GFP and pcDNA3.1,
pcDNA3.1-VTN_rs704:C, or pcDNA3.1-VTN_rs704:T, using
TransIT-LT1 Transfection Reagent (Mirus Bio, Madison,
WI, USA) for HEK293 or Lipofectamine 3000 Transfection
Reagent (Thermo Fisher Scientific) for ARPE-19, according
to the manufacturer’s instructions. Vitronectin expression
was investigated in cell pellets and supernatants via sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) and western blot analysis. The applied antibody
against vitronectin (see Supplementary Table S2) is a mono-
clonal antibody generated against human plasma-derived
vitronectin. It detects the full length (75 kDa) isoform,
as well as the 65 kDa subfragment, but not the 10-kDa
subfragment of the cleaved isoform (see also Supplementary
Fig. S2).
To isolate and purify vitronectin isoforms, pEXPR-
IBA103-VTN_rs704:C or pEXPR-IBA103-VTN_rs704:T were
transfected into HEK293 by the calcium phosphate method
as described previously.32 Seven hours after transfec-
tion, the culture medium was replaced by FCS-free
DMEM high-glucose medium containing 100 U/mL peni-
cillin/streptomycin and 500 μg/mL G418, and cells were
cultured for 72 hours. Strep-tagged VTN_rs704:C and
VTN_rs704:T were purified with the Twin-Strep-tag purifi-
cation kit from the supernatant of transfected HEK293
cells according to the manufacturer’s protocol. Concentra-
tions of purified proteins were determined using the Bio-
Rad DC protein assay kit (Bio-Rad Laboratories, Hercules,
CA, USA), as well comparative western blot analysis with
recombinant vitronectin protein (10424-H08H; Sino Biolog-
ical, Inc., Beijing, China). As a control, HEK293 cells were
transfected with empty pEXPR-IBA103 expression vector,
and the cultivation medium of these cells was subjected
to purification procedures identical to that for cells trans-
fected with vitronectin expression vectors. Enrichment and
purification were controlled via silver staining, Coomassie
Blue staining, and western blot analysis (see Supplementary
Fig. S3).
SDS-PAGE and Western Blot Analysis
SDS-PAGE and western blot analysis were performed
as described previously.30,33,34 Non-reducing condi-
tions were established by omitting the reducing agent
β-mercaptoethanol from Lämmli buffer35 in gels containing
7% acrylamide. Densitometry was done with Image Studio
software (LI-COR Biosciences, Lincoln, NE, USA).
Blue Native PAGE
All supplies (gels, buffers, standard) for Blue native PAGE
were purchased from the Invitrogen NativePAGE range
(Thermo Fisher Scientific). Blue native gel electrophore-
sis was performed according to the manufacturer’s instruc-
tions. For western blot analyses, the NuPAGE Transfer Buffer
(Thermo Fisher Scientific) system for wet blotting was used
according to the manufacturer’s instructions.
Binding of Vitronectin Isoforms to Cells
Vitronectin binding to cell lines (ARPE-19, hiPSC–RPE,
porcine RPE, Y79, and HUVECs) was assessed as described
previously,30,36 with the following modifications. Cells
grown to confluency in one 10-cm plate (ARPE-19), six
12-well transwell filters inserts (hiPSC–RPE), or one T25
flask (HUVECs), as well as to maximal cell concentration in
two T25 flasks (Y79), were suspended as combined samples
in 600 μL Dulbecco’s phosphate-buffered saline (DPBS;
Sigma-Aldrich). Porcine RPE cells were dissected from fresh
eyes obtained from a local slaughterhouse as described
previously.37 Cells obtained from one eye were resuspended
in 600 μL DPBS. Then, 200 μL of the cell suspensions
were incubated with 1 mL VTN_rs704:C-containing medium,
VTN_rs704:T-containing medium, or control medium (from
supernatant of transfected HEK293 cells) for 60 minutes,
with subsequent washing steps as described previously.30,36
Production of ARPE-19 Cell-Derived ECM
Containing Overexpressed Vitronectin Isoforms
To generate cell-derived ECM, ARPE-19 cells were
co-transfected with pcDNA3.1-GFP and pcDNA3.1,
pcDNA3.1_VTN_rs704:C, or pcDNA3.1_VTN_rs704:T using
Lipofectamine 3000 Transfection Reagent (Thermo Fisher
Scientific) according to the manufacturer’s instructions. After
24 hours, GFP fluorescence was microscopically assessed
as a marker for transfection efficiency. Transfected ARPE-19
cells were enzymatically dissociated from the cell culture
plate with Gibco Trypsin–EDTA (Thermo Fisher Scientific)
and seeded onto 12- or 24-well transwell filter inserts
(0.4-μm pore size; Greiner Bio-One), with 4 × 105 cells or
2 × 105 cells per transwell filter insert in DMEM/HamsF12
containing 10% FCS and 100 U/mL penicillin/streptomycin.
After 24 hours, the medium was changed to FCS-free
medium containing 100 U/mL penicillin/streptomycin,
200 μg/mL dextran sulfate (Carl Roth GmbH, Karl-
sruhe, Germany), and 30 μg/mL ascorbic acid (Cayman
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Chemical, Ann Arbor, MI, USA), as described in McLenachan
et al.38 Confluent ARPE-19 monolayers were cultured in this
medium for 4 weeks with media changes three times per
week. Transwell filter inserts were then decellularized by
incubating them with 0.5% Triton X-100 and 20-mM NH4OH
in DPBS for 5 minutes at 37°C, as described in Fernandez-
Godino et al.39 Immunolabeling was performed as described
in Friedrich et al.30 and Schmid et al.40 using a quarter of a
12-well transwell filter insert for each staining. Pictures were
taken with a confocal laser scanning microscope (FV3000
Fluoview; Olympus Life Sciences, Hamburg, Germany).
Signal intensity and average cluster size were measured
using ImageJ (National Institutes of Health, Bethesda,
MD, USA).
Adhesion Assay with Purified Recombinant
Vitronectin Isoforms
HiPSC–RPE cells were enzymatically dissociated from
12-well transwell filter inserts with Gibco TrypLE Select
(Thermo Fisher Scientific) for 40 minutes at 37°C. Subse-
quently, cells from a single filter were resuspended in
600 μL medium (deprived of KnockOut Serum Replace-
ment), after which 100 μL of the cell suspension was mixed
with 1.5 μg/mL of purified recombinant vitronectin isoforms
(VTN_rs704:C or VTN_rs704:T) or equal volumes of control
eluates and then transferred onto a 96-well plate. After
24 hours of incubation at 37°C, the medium was removed,
and cells were incubated with Hoechst 33342 (1:1000
diluted in DPBS) for 10 minutes at room temperature.
After staining, cells were washed three times for 5 minutes
each with DPBS. Fluorescence images of adherent cells
were taken with a Nikon Eclipse microscope (TE-2000-U;
Nikon, Tokyo, Japan). Cell attachment was quantified by
fluorescence intensity measurement (excitation/emissions,
360/490 nm) using a Spark multimode microplate reader
(Tecan Group AG, Männedorf, Switzerland).
The adhesion assay with primary porcine RPE cells was
performed similarly, with minor modifications. Porcine RPE
cells were dissected from fresh eyes obtained from a local
slaughterhouse as described previously.37 Cells obtained
from one eye were resuspended in 600 μL medium (deprived
of KnockOut Serum Replacement), and 100 μL of the cell
suspension was applied to the adhesion assay with an
incubation time of 18 hours. Due to the strong pigmenta-
tion, fluorescent staining with Hoechst 33342 was omitted.
Images from each 96-well plate were taken at 4× magnifi-
cation with a Nikon Eclipse microscope, and RPE cells were
counted using ImageJ.
The HUVEC adhesion assay was performed likewise, with
minor modifications. Briefly, cells from a T25 cell culture
flask were enzymatically dissociated with 1 mL of Trypsin–
EDTA for 1 minute at room temperature and resuspended in
1.2 mL FCS-free cultivation medium. Then, 100 μL of the cell
suspension was applied to the adhesion assay. Incubation
time was 20 minutes.
Adhesion Assay on ARPE-19-Derived ECM
A volume of 200 μL hiPSC–RPE, 250 μL porcine RPE, or
200 μL HUVEC cell suspension (prepared as described in the
preceding paragraph) was transferred onto a 24-well tran-
swell filter insert coated with ARPE-19-derived ECM. After
40 minutes (hiPSC–RPE or porcine RPE cells) or 20 minutes
(HUVECs), the culture medium was removed. The hiPSC–
RPE cells or HUVECs were incubated with Hoechst 33342
as described above. Images from each transwell filter insert
were taken at 4× magnification with a Nikon Eclipse micro-
scope. Cells were counted using ImageJ.
HUVEC Tube Formation Assay
Endothelial tube formation in response to vitronectin expo-
sure was examined in vitro with HUVECs as described
in Ponce41 with the following modifications: First, 8.5 ×
103 HUVECs/well were seeded onto a 96-well plate coated
with 37.5 μL Geltrex LDEV-Free Reduced Growth Factor
Basement Membrane Matrix (Thermo Fisher Scientific). Cells
were then cultured in 100 μL EGMPlus Endothelial Cell
Growth Media containing 1/3 EGMPlus SingleQuots supple-
ments, 50 ng/mL VEGF (PeproTech, Hamburg, Germany),
and 5 μg/mL purified recombinant vitronectin (VTN_rs704:C
or VTN_rs704:T) or equal volumes of control eluate. Three
to five simultaneous tests per each treatment were included
in one independent replicate. After 16 hours, images from
each well were captured at 4× magnification with a Nikon
Eclipse microscope. Cumulative tube length was quantified
using the Angiogenesis Analyzer in ImageJ as described
previously.42
HUVEC Migration Assay
HUVEC migration was determined using the scratch-wound
assay, as described in Liang et al.43 with the following
modifications. HUVECs were seeded on a 96-well plate and
incubated in EGMPlus Endothelial Cell Growth Media with
EGMPlus SingleQuots supplements. After 24 hours, conflu-
ent cell monolayers were scratched using a WoundMaker
(Essen BioScience, Ann Arbor, MI, USA). Cell debris was
removed by washing with DPBS, and injured monolayers
were incubated in EGMPlus Endothelial Cell Growth Media
with EGMPlus SingleQuots supplements but without FCS,
containing 50 ng/mL VEGF, and 20 μg/mL of purified recom-
binant vitronectin (VTN_rs704:C or VTN_rs704:T) or equal
volumes of control eluate. Four to seven simultaneous tests
per treatment were included in one independent replicate.
After 0 and 14 hours, images from each well were captured at
4× magnification with a Nikon Eclipse microscope. Scratch
areas were determined using ImageJ, and migration ability
was defined as the percentage area closed after 14 hours of
incubation.
Statistical Analyses
Statistical analyses were performed with the XLSTAT add-
in software. The Shapiro–Wilk normality test was applied
to assess normality of the data. Data following a Gaus-
sian distribution were analyzed using Student’s t-test (two
experimental groups) or ANOVA test with Tukey’s multiple
comparison test (more than two experimental groups). Data
not following a Gaussian distribution were analyzed with the
Mann–Whitney U test (two experimental groups) or Kruskal–
Wallis test with post ad hoc Dunn’s multiple comparison
test and Bonferroni correction (more than two experimental
groups).
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RESULTS
Endogenous Vitronectin Expression in Retinal
and Non-Retinal Cell Lines
Searching for in vitro model systems applicable to analyz-
ing an influence of rs704 on vitronectin functionality, we
tested endogenous vitronectin expression in different reti-
nal and non-retinal cells frequently used as model systems
to investigate AMD-associated molecular pathomechanisms
or functionality of retinal disease-related proteins.12,34,44
These included human RPE cell lines ARPE-19 and hiPSC–
RPE, human retinoblastoma cell lines Y79 and WERI-Rb1,
endothelial cell line HUVEC, and HEK293 cells.
Endogenous vitronectin mRNA expression, assessed
using semi-quantitative RT-PCR (Fig. 1A), was only detected
in the two retinoblastoma-derived cell lines Y79 and WERI-
Rb1 and, to a much weaker extent, in the two RPE cell lines
ARPE-19 and hiPSC–RPE. Western blot analysis, however,
failed to detect vitronectin protein in any of the cell lines
tested, even after multiple attempts to increase sensitivity
(Fig. 1B).
In the human retina, VTN is expressed in RPE and
neural retina4,14,15 (see also the eyeIntegration database,
https://eyeintegration.nei.nih.gov). An effect of rs704 on
mRNA expression in these tissues was measured by a
semi-quantitative sequencing approach on hiPSC–RPE cells
and neural retinal samples derived from different donors,
which were heterozygous for rs704 (identified via genomic
sequencing; see Supplementary Fig. S2). A dilution series
with different concentrations of the vitronectin mRNA vari-
ants (VTN_rs704:C and VTN_rs704:T) showed that the rs704
polymorphism of the VTN gene is resolvable as a heterozy-
gous peak in the sequence chromatogram up to the highest
dilution of 1:5. Differences in VTN_rs704:C and VTN_rs704:T
concentrations are traceable at changes in the electrophero-
gram peaks of the T and the C allele at the rs704 position
from a twofold increase in one of the two variants (Fig. 1C).
Analyzing vitronectin mRNA expression in the heterozygous
hiPSC–RPE cell lines and neural retinal samples (Fig. 1D)
revealed similar electropherogram peaks for the T and the
C allele at the rs704 position (Fig. 1D), suggesting similar
levels of VTN_rs704:C and VTN_rs704:T transcripts and thus
no significant effect of rs704 on vitronectin mRNA expres-
sion in these samples.
Effect of rs704 on Vitronectin Protein Expression,
Processing, and Oligomerization
Next, an effect of rs704 on vitronectin protein expres-
sion and secretion was analyzed. To this end, HEK293 and
ARPE-19 cells were transfected with expression vectors for
the two vitronectin isoforms: the non-AMD-risk-associated
isoform VTN_rs704:C and the AMD-risk-associated isoform
VTN_rs704:T. Western blot analysis followed by densito-
metric evaluation (see Supplementary Fig. S2) determined
vitronectin processing and vitronectin protein expression
in cells and supernatants at two different time points (48
hours and 72 hours after transfection) (Fig. 2A). Heterol-
ogous expression of vitronectin isoforms in HEK293 cells
revealed a statistically significant increase in intracellu-
lar amounts of AMD-risk-associated VTN_rs704:T relative
to the non-AMD-risk-associated VTN_rs704:C (48 hours,
3.99 ± 2.88-fold increase; 72 hours, 5.66 ± 1.91-fold
increase; P < 0.05 for both time points). Similarly, an
FIGURE 1. Endogenous vitronectin expression in retinal and non-
retinal cell lines. (A) RT-PCR analysis of VTN gene expression in
ARPE-19, hiPSC–RPE, Y79, WERI-Rb1, HUVEC, and HEK293 cells.
Expression vectors containing cDNA of non-AMD-risk-associated
VTN served as positive control; no template was added to the
negative control. GUSB gene expression was assessed as control
for RNA integrity. (B) Western blot analysis of vitronectin protein
expression in ARPE-19, hiPSC–RPE, Y79, WERI-Rb1, HUVEC, and
HEK293 cells. HEK293 cells transfected with expression vectors for
VTN_rs704:C served as positive control. Cell lysates were subjected
to western blot analyses using antibodies against vitronectin. The
ACTB immunoblot was performed as loading control. (C) Titra-
tion series with recombinant VTN cDNA isoforms derived from
the non-risk (rs704:C) or the risk (rs704:T) haplotype (ratio of C:T
allele given in the figure). Isoforms were determined by sequence
analysis. VTN_rs704:C and VTN_rs704:T transcription in hiPSC–
RPE cells (D) or human retinal tissues (E) of different donors
was analyzed by semi-quantitative sequencing of allele-specific
transcripts. Non-AMD-risk-associated and AMD-risk-associated alle-
les at the vitronectin gene locus were determined by genomic
sequencing of variant rs704 (see Supplementary Fig. S4). Expres-
sion of the non-AMD-risk-associated and AMD-risk-associated VTN
mRNA isoforms was investigated by cDNA sequencing of variant
rs704.
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FIGURE 2. Effect of rs704 on vitronectin protein expression, processing, and oligomerization. (A) Western blot analysis of VTN_rs704:C or
VTN_rs704:T protein expression after heterologous expression. HEK293 and ARPE-19 cells were transfected with expression vectors for
VTN_rs704:C or VTN_rs704:T or with an empty expression vector (pcDNA3.1). Co-transfection with a GFP expression vector was performed
as control. Forty-eight and 72 hours after transfection, cell pellets and supernatants (SNs) of transfected cells were subjected to western blot
analysis with antibodies against vitronectin and GFP. The ACTB immunoblot served as control. After densitometric quantification, vitronectin
signals from cell pellets and supernatants were normalized against GFP. Data represent the mean ± SD of four biological replicates, calibrated
against VTN_rs704:C. Asterisks indicate statistically significant differences (*P < 0.05, Mann–Whitney U test). (B) Non-reducing SDS-PAGE
and (C) Blue native PAGE with purified recombinant vitronectin isoforms, followed by western blot analysis against vitronectin.
increase of VTN_rs704:T protein relative to VTN_rs704:C was
evident in the supernatant of the transfected HEK293 cells
(48 hours, 3.03 ± 2.52-fold increase; 72 hours, 3.47 ±
2.05-fold increase; P < 0.05 for both time points).
Comparable results were obtained after heterologous
expression of vitronectin isoforms in ARPE-19. Compared
to VTN_rs704:C, the AMD-risk-associated VTN_rs704:T
showed a statistically significant increase in intracellu-
lar protein level (48 hours, 4.19 ± 2.20-fold increase;
72 hours, 5.60 ± 3.83-fold increase; P < 0.05 for
both time points), as well as in the supernatant (48
hours, 4.17 ± 2.16-fold increase, P < 0.05; 72 hours,
1.55 ± 1.36-fold increase, P > 0.05).
The immunoblots of the supernatants demonstrated that
VTN_rs704:T was less susceptible to endogenous cleav-
age, resulting in higher amounts of uncleaved, single-
chain vitronectin and lower amounts of cleaved vitronectin,
compared to VTN_rs704:C (Fig. 2A).
We further investigated the impact of rs704 on vitronectin
oligomerization, which is thought to play an important
role in cell adhesion, ECM organization, or the forma-
tion of extracellular deposits.19,45,46 Vitronectin oligomer-
ization is reported to be stabilized by disulfide bonds
and non-covalent interactions.19 To follow the formation
of oligomers stabilized by disulfide bonds, non-reducing
SDS-PAGE (Fig. 2B) was performed as described previ-
ously.47,48 Oligomerization stabilized by non-covalent inter-
actions was addressed via Blue native PAGE (Fig. 2C)
as described previously.49 Despite the effect of rs704 on
endogenous proteolytic cleavage of the two vitronectin
isoforms (Fig. 2A), rs704 did not affect oligomeriza-
tion of the two vitronectin isoforms: non-reducing SDS-
PAGE and Blue native PAGE both demonstrated similar
oligomerization patterns for VTN_rs704:C and VTN_rs704:T
(Figs. 2B, 2C).
Binding Capacity of Vitronectin Isoforms to
Different Retinal and Non-Retinal Cell Lines
Under physiological conditions, soluble vitronectin binds to
various cell surfaces.50 We therefore investigated an influ-
ence of the rs704-associated amino acid exchange on the
capacity of the two vitronectin isoforms to bind to retinal
and endothelial cells (Fig. 3). All tested cell lines (ARPE-
19, hiPSC–RPE, porcine RPE, HUVEC, and Y79) bound
both vitronectin isoforms (VTN_rs704:C and VTN_rs704:T).
However, a striking difference was evident in bind-
ing efficiency. Compared to the non-AMD-risk-associated
VTN_rs704:C, the AMD-risk-associated VTN_rs704:T protein
revealed a strongly decreased binding capacity to all cell
lines tested (reduction to 21.3% ± 19.4% at ARPE-19,
34.8% ± 37.0% at hiPSC–RPE, 10.2% ± 6.7% at porcine RPE,
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FIGURE 3. Binding capacity of vitronectin isoforms to different reti-
nal and non-retinal cell lines. ARPE-19, hiPSC–RPE, porcine RPE
(pRPE), HUVEC, and Y79 cells were incubated for 60 minutes with
vitronectin-containing input (I, supernatants of HEK293 cells trans-
fected with expression vectors for VTN_rs704:C and VTN_rs704:T,
adjusted to obtain comparable concentrations of the vitronectin
isoforms) or control input. Cells were then centrifuged and inten-
sively washed. Vitronectin binding was assessed by subjecting
cell pellets (P) to western blot analysis with antibodies against
vitronectin. The ACTB immunoblot was performed as loading
control. After densitometric quantification, vitronectin signals were
normalized against ACTB and vitronectin in the input. Data repre-
sent the mean ± SD of four (hiPSC–RPE and pRPE), five (ARPE-19
and HUVECs), or six (Y79) biological replicates, calibrated against
VTN_rs704:C. Asterisks indicate statistically significant differences
(*P < 0.05, Mann–Whitney U test).
27.9% ± 19.2% at HUVEC, and 37.1% ± 30.3% for Y79 cells;
P < 0.05 for all cell lines).
Effect of rs704 on AMD-Associated Processes
In the retina, extracellular vitronectin protein was mainly
detected in sub-RPE regions, namely in Bruch’s membrane
and the retinal vasculature.14 As vitronectin is a known cell
adhesion and spreading factor contributing to ECM orga-
nization (reviewed in Leavesley et al.3), we analyzed the
role of the vitronectin isoforms in ECM deposition, RPE and
endothelial adhesion, and spreading of endothelial cells, all
processes associated with AMD pathology51 (reviewed in
Kleinman and Ambati24 and Campochiaro25).
Effect of Vitronectin on Extracellular
Microenvironment
To assess effects of vitronectin isoforms on ECM orga-
nization, we examined ECM deposition by ARPE-19 cells
that were transfected with expression vectors for the
two vitronectin isoforms, VTN_rs704:C or VTN_rs704:T, as
described previously.38,39
After 4 weeks, ARPE-19 cells heterologously express-
ing vitronectin exhibited large extracellular vitronectin
aggregates extending along the produced ECMs (Fig. 4A).
Quantification revealed a 2.82 ± 1.89-fold increase in
vitronectin signal intensity and a 1.99 ± 1.04-fold increase in
vitronectin cluster size in the ECMs containing the AMD-risk-
associated isoform VTN_rs704:T compared to ECMs contain-
ing non-AMD-risk-associated isoform VTN_rs704:C (P <
0.05) (Fig. 4B). Laminin staining reflected disorganized fibers
and aggregates in all ECMs (Fig. 4A). The overall amount of
laminin (Fig. 4B) and its assembly (Fig. 4C) were not affected
by heterologous expression of vitronectin.
Fibronectin appeared as densely packed aggregates in
ECMs of non-vitronectin expressing cells. In ECMs contain-
ing vitronectin, these aggregates extended and formed
fibers (Fig. 4A), with an increase in total fibronectin
signal intensity (VTN_rs704:C, 1.50 ± 0.64; VTN_rs704:T,
1.95 ± 1.15, compared to control) (Fig. 4B). The increase
in fibronectin cluster size was 1.44 ± 0.64 for VTN_rs704:C
and 2.50 ± 1.12 for VTN_rs704:T. The AMD-risk-associated
VTN_rs704:T protein exerted a stronger effect on fibronectin
levels and cluster sizes than VTN_rs704:C (P < 0.05 between
VTN_rs704:T and control) (Figs. 4B, 4C).
Elastin revealed a similar appearance than fibronectin
staining (Fig. 4A), although the increase in signal inten-
sity was not as pronounced (VTN_rs704:C, 1.08 ± 0.05;
VTN_rs704:T, 1.12 ± 0.06, compared to control; P <
0.05 between VTN_rs704:T and control) (Fig. 4B). Both
vitronectin isoforms had a similar effect on elastin clus-
ter size (increase to 1.62 ± 0.45 for VTN_rs704:C and
1.51 ± 0.34 for VTN_rs704:T compared with control;
P < 0.05 between both vitronectin isoforms and control)
(Fig. 4C).
In the ECMs of non-vitronectin expressing cells, collagen
VI was evenly distributed along the ECM without promi-
nent cluster or fiber formation. In vitronectin-containing
ECMs, we observed a notable aggregation of collagen
VI (Fig. 4A, shown in the merged picture of vitronectin
and collagen VI staining). Although collagen VI staining
failed to show a statistically significant increase in total
signal intensity (Fig. 4B), vitronectin expression was asso-
ciated with an increase in collagen VI cluster size. Again,
AMD-risk-associated VTN_rs704:T exerted a stronger effect
than non-AMD-risk-associated VTN_rs704:C (1.45 ± 0.42 for
VTN_rs704:C and 1.81 ± 0.35 for VTN_rs704:T compared
to control; P < 0.05 between VTN_rs704:T and control)
(Fig. 4C).
Effect of Vitronectin on RPE and Endothelial Cell
Adhesion
An effect of the vitronectin isoforms on RPE adhesion was
analyzed by testing adherence of suspended hiPSC–RPE
cells to the cell culture dish surface in the presence of
purified recombinant VTN_rs704:C, VTN_rs704:T, or control
eluate. After washing, adherent cells were labeled, and fluo-
rescence intensity was measured fluorometrically (Fig. 5A).
RPE adhesion increased to 4.24 ± 0.99 in VTN_rs704:C and
to 3.78 ± 0.86 in VTN_rs704:T treated samples compared
with control (P < 0.05 between vitronectin treated samples
and control). Vitronectin-dependent RPE adhesion was also
investigated using primary RPE cells, freshly isolated from
pig eyes. Due to the strong pigmentation, adhesion was
not followed fluorometrically, but microscopically. Again,
the presence of recombinant vitronectin increased porcine
RPE cell adhesion compared with control treatment (1.92 ±
0.53 for VTN_rs704C and 1.96 ± 0.83 for VTN_rs704:T; P <
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FIGURE 4. Effect of vitronectin isoforms on ECM deposition by ARPE-19 cells. (A) ARPE-19 cells transfected with expression vectors for
VTN_rs704:C or VTN_rs704:T or with an empty expression vector (pcDNA3.1) were incubated for 4 weeks on transwell filter inserts. After
4 weeks, the inserts were decellularized and subjected to immunostaining with antibodies against vitronectin (α-VTN), laminin (α-LAM),
fibronectin (α-FN), elastin (α-ELA), or collagen VI (α-COL VI). Confocal microscopy images were taken at 10× magnification. Scale bars:
100 μm. (B) Fluorescence intensity and (C) average cluster size were measured using ImageJ. Data represent the mean ± SD of eight
(vitronectin), five (laminin, fibronectin, and elastin), or six (collagen VI), independent replicates, calibrated against the control. Asterisks
indicate statistically significant differences (*P < 0.05, Kruskal–Wallis test, followed by Dunn’s multiple comparison test with Bonferroni
correction).
0.05 between vitronectin treated samples and control). Inter-
estingly, opposite results were obtained with endothelial
HUVECs (Fig. 5B). The presence of recombinant vitronectin
slightly decreased HUVEC adhesion and thus fluorescence
intensity to 0.90 ± 0.05 for VTN_rs704:C and 0.83 ± 0.09 for
VTN_rs704:T (P < 0.05 between VTN_rs704:T and control).
In an alternative approach, we tested RPE and endothe-
lial cell adhesion to vitronectin-containing ECM deposited
by ARPE-19. ECM containing recombinant vitronectin facili-
tated increased adherence of hiPSC–RPE cells (1.79 ± 0.41
for VTN_rs704C and 1.84 ± 0.25 for VTN_rs704:T; P < 0.05
between control and vitronectin-containing ECMs), porcine
RPE cells (2.92 ± 1.71 for VTN_rs704C and 1.73 ± 0.42
for VTN_rs704:T; P < 0.05 between VTN_rs704:C-containing
ECM and control), as well as of HUVECs (1.52 ± 0.36 for
VTN_rs704C and 1.59 ± 0.56 for VTN_rs704:T; P < 0.05
between control and vitronectin-containing ECMs).
Effect of Vitronectin on Angiogenesis-Related
Processes
Finally, we assessed effects of vitronectin isoforms on
angiogenesis by testing HUVEC migration and the abil-
ity of HUVEC to form three-dimensional capillary-like
tubular structures. The presence of recombinant purified
VTN_rs704:C but not VTN_rs704:T slightly reduced HUVEC
migration (VTN_rs704:C, 93.3% ± 5.0% compared to control;
P < 0.05 between VTN_rs704:C and control, as well as
between VTN_rs704:C and VTN_rs704:T) (Fig. 6A, Supple-
mentary Fig. S5). Both vitronectin isoforms decreased tubu-
lar structure formation by HUVECs (reduction to 78.8% ±
27.2% by VTN_rs704:C and 85.2% ± 11.9% by VTN_rs704:T
compared to control; P < 0.05 between control and both
vitronectin isoforms) (Fig. 6B).
DISCUSSION
The present study investigates the influence of AMD-
associated genetic non-synonymous VTN variant rs704
on the functionality of the resulting vitronectin protein
isoforms. We provide evidence that rs704 significantly alters
expression, secretion, and processing of the vitronectin
protein. In addition, rs704 affects the ability of vitronectin to
bind to retinal and endothelial cells. Interestingly, the AMD-
risk-associated and non-AMD-risk-associated vitronectin
isoforms reveal differential effects on ECM production by
ARPE-19 cells, specifically on deposition and clustering of
ECM constituents such as fibronectin, elastin, and collagen
VI. Vitronectin also affects RPE and endothelial cell adhe-
sion, as well as tubular-like structure formation by endothe-
lial cells. In consequence, our data suggest a close functional
correlation between rs704 and vitronectin in AMD pathogen-
esis.
The cDNA analysis of hiPSC–RPE cells and human reti-
nal tissues heterozygous for rs704 revealed no effect of
rs704 on the transcriptional activity of VTN. This is consis-
tent with data provided by the Genome-Tissue Expres-
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FIGURE 5. Effect of vitronectin isoforms on RPE and endothelial cell adhesion. (A) Suspended hiPSC–RPE cells, (B) freshly isolated porcine
RPE cells (pRPE), or (C) HUVECs were incubated for 24 hours (A), 18 hours (B), or 20 minutes (C) in the presence of purified recombinant
VTN_rs704:C, VTN_rs704:T, or control eluate. Subsequently, cell adhesion was determined measuring fluorescence of fluorescently labeled
cells in a spectrophotometer (A, C) or counting cells from 4× micrographs (B) using ImageJ. (D) Suspended hiPSC–RPE cells, (E) freshly
isolated pRPE, or (F) HUVECs were incubated for 40 minutes (D, E) or 5 minutes (F) on VTN_rs704:C- or VTN_rs704:T-containing ECM or on
control ECM. Subsequently, adherent cells were determined by counting cells (fluorescently labeled in D and F) from 4× micrographs with
ImageJ. Data represent mean ± SD of seven (A), four (B, E), or five (C, D, F) independent replicates, calibrated against the control. Asterisks
indicate statistically significant differences (*P < 0.05, Kruskal–Wallis test, followed by Dunn’s multiple comparison test and Bonferroni
correction). Micrographs shown in the figure were taken at 10× magnification (standard, 200 μm).
FIGURE 6. Effect of vitronectin isoforms on HUVEC migration and tube formation. (A) To investigate an effect of vitronectin isoforms on
endothelial migration, a scratch assay was performed with HUVECs cultivated in the presence of VTN_rs704:C, VTN_rs704:T, or control eluate
(see Supplementary Fig. S5), and cell migration was defined as the percentage area closed after 14 hours of incubation. Data represent mean
± SD of six independent replicates, calibrated against the control. (B) HUVECs were cultivated in the presence of recombinant VTN_rs704:C,
VTN_rs704:T, or control eluate. After 16 hours, the formation of tubular-like structures was followed microscopically (standard, 400 μm).
The length of tubular-like structures was measured using ImageJ. Data represent mean ± SD of 11 independent replicates calibrated against
the control. Asterisks indicate statistically significant differences (*P < 0.05, Kruskal–Wallis test, followed by Dunn’s multiple comparison
test and Bonferroni correction).
sion Project (https://gtexportal.org). Bioinformatic analy-
ses including genotype and gene expression data from 49
(non-retinal) tissues revealed no differential effect of the
rs704 polymorphism on vitronectin mRNA expression, thus
excluding rs704 as an expression quantitative trait locus
for VTN in the 49 tissues analyzed. However, heterologous
expression of the different vitronectin isoforms shows an
impact of rs704 on vitronectin protein expression. This is
Downloaded from iovs.arvojournals.org on 12/07/2020
Vitronectin Involvement in AMD Pathogenesis IOVS | December 2020 | Vol. 61 | No. 14 | Article 2 | 10
in agreement with data from a genotype-protein association
analysis in human plasma samples from 3301 individuals.52
In that study, an increase in vitronectin serum levels was
associated with AMD-risk variant rs704, classifying rs704
as a protein quantitative trait locus.52 Increased expres-
sion of VTN_rs704:T might be a consequence of different
codon usage, which can influence translation kinetics.53,54
The methionine encoding triplet codon AUG (adenine–
uracil–guanine; 22.3 in 1000, found in the risk allele) has a
higher frequency than the threonine encoding triplet codon
ACG (adenine–cytosine–guanine; 6.2 in 1000).55 Moreover,
rs704:C>T induces an exchange from a polar (threonine) to
an unpolar amino acid (methionine). Alterations in transla-
tion rate or amino acid composition can affect protein fold-
ing and translocation into the endoplasmic reticulum or the
Golgi apparatus (summarized in Lodish56 and Hurtley and
Helenius57).
As observed before,26,58,59 rs704 decreases cleavage of
full-length vitronectin to a disulfide bond cross-linked form
comprised of the 65- and 10-kDa subunits. Studies on func-
tional differences between the cleaved and non-cleaved
vitronectin or between VTN_rs704:C and VTN_rs704:T are
rare and report controversial results.59–61 Although Gibson
and colleagues60 failed to detect differences between non-
cleaved and cleaved vitronectin in binding to heparin
and plasminogen activator inhibitor-1 (PAI-1), Chain and
colleagues59 reported a distinct conformational change after
vitronectin cleavage that “buried” a phosphorylation site at
amino acid position 378, thus impairing vitronectin phos-
phorylation. Hazawa and colleagues61 found that PAI-1 simi-
larly inhibited cleavage of VTN_rs704:C and VTN_rs704:T,
and only the non-cleaved but not the cleaved vitronectin
protected endothelial cells against radiation-induced cell
death.
Our study demonstrated an effect of rs704 on cell binding
of vitronectin, which can interact with a variety of molecules
on cell surfaces, including integrin receptors,62–64 urokinase
receptor,65,66 heparin,67,68 or lipids.69 Upon interaction with
a binding partner, vitronectin changes its structural and func-
tional capacities (reviewed in Preissner and Reuning50). The
decreased cell surface binding of the AMD-risk-associated
vitronectin isoform (VTN_rs704:T) could consequently affect
its functionality on various cellular, vitronectin-regulated
processes.
Vitronectin is a key constituent of the ECM. In contrast
to classical ECM proteins such as collagen, fibronectin,
or laminin, which have structural functions, vitronectin
is thought to operate as a “matricellular” protein, acting
in particular as a modulator of the cell–ECM interface
and exerting regulatory functions in a variety of cellular
processes such as cell adhesion, angiogenesis, and matrix
remodeling (reviewed in Leavesley et al.,3 Preissner and
Reuning,50 and Schvartz et al.70). ECM produced by ARPE-
19 cells is composed of characteristic Bruch’s membrane
proteins38,39 and supports primary RPE cells to acquire
and maintain the RPE phenotype.38 Therefore, despite the
limitation of ARPE-19 cells for studying certain aspects of
RPE function due to low polarization, pigmentation, and
transepithelial resistance,71–73 they frequently serve as a
model system to recreate Bruch’s membrane pathology in
culture12,38,39,74,75 (reviewed in Fields et al.76). In our study,
heterologous expression of vitronectin by ARPE-19 cells
increased deposition and clustering of ECM constituents
such as fibronectin, elastin, and collagen VI. This could be
a consequence of the matricellular activity of vitronectin.
Several studies have shown that vitronectin binds colla-
gen.77–79 Higher amounts of deposited vitronectin can thus
bind higher amounts of collagen, consequently enhancing
collagen accumulation at the site of vitronectin deposition,
as observed in our analysis. Collagen, on the other hand,
interacts with fibronectin and stimulates the formation of a
stable fibronectin meshwork.80–82 Alternatively, vitronectin
may directly affect fibronectin deposition; a study by Pankov
and colleagues83 observed that binding of vitronectin to its
integrin receptor on the cell surface initiated the assembly of
fibronectin, eventually leading to fibronectin fibrillogenesis.
Fibronectin in turn can bind elastin84 and promote elastin
deposition.85 Interestingly, the AMD-risk-associated isoform
VTN_rs704:T showed increased deposition and larger cluster
size than the non-AMD-risk-associated VTN_rs704:C, which
is consistent with the increased expression of VTN_rs704:T
observed in our study and in Sun et al.52 VTN_rs704:T
also exerted stronger effects on levels and clustering of
fibronectin, elastin, and collagen VI when compared to
VTN_rs704:C. A follow-up in-depth characterization of ECM
structure (including scanning and transmission electron
microscopy) and ECM composition, as well as its conse-
quences on RPE homeostasis, is in progress. Despite the arti-
ficial in vitro system, results reproducibly show differences
of the two vitronectin isoforms in their ECM deposition and
in their effect on other ECM components. The observed
functional difference between the two isoforms might also
affect ECM deposition in vivo and thus contribute to AMD
pathology. AMD eyes characteristically reveal alterations in
ECM integrity, specifically the emergence of basal laminar
deposits,86–89 which may cause an impaired diffusion of
waste products and nutrients through the RPE (reviewed in
Birch and Liang90 and Bird91). Subsequent RPE stress might
result in increased RPE death and growth factor produc-
tion, all characteristic processes in geographic atrophy or
choroidal neovascularization (reviewed in Somasundaran
et al.89 and Al-Zamil and Yassin92). Moreover, vitronectin
is a major component of drusen.4–6 Increased deposition
of risk-associated VTN_rs704:T and concurrent clustering
of ECM components such as fibronectin, elastin, and colla-
gen VI could thus be related to the formation of abnormal
deposits in Bruch’s membrane, hence contributing to AMD
development.
Vitronectin plays a key role in the adhesion of cells to
the ECM.93,94 Consistent with this, the addition of recom-
binant vitronectin or vitronectin-containing ECM strongly
increased adhesion of porcine and hiPSC-derived RPE
cells. Vitronectin-containing ECM also enhanced adhesion
of HUVECs, whereas recombinant vitronectin exerted a
different effect: In the latter experiment, vitronectin had
no adhesive properties, and the risk-associated isoform
VTN_rs704:T even showed a very slight, anti-adhesive effect
on HUVECs. This could be the result of a competition
of integrin/urokinase receptors and PAI-1 for binding to
vitronectin. HUVECs express high amounts of PAI-1,95–97
which is known to block integrin or urokinase receptor-
mediated adhesion due to a close proximity of their respec-
tive binding sites on vitronectin.98–105 Increased attachment
of HUVECs to vitronectin-containing ECM could in turn be
mediated by other ECM components such as collagen VI
or fibronectin, which also exhibited increased deposition in
these ECMs.
Interestingly, the two vitronectin isoforms revealed simi-
lar effects on cell adhesion, but their capacity to bind to
cell surfaces significantly differed. This apparent discrep-
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ancy could be explained by the fact that our cell-binding
assays show the physical interaction between vitronectin
and cells, which can be mediated by a variety of cell surface
molecules, such as lipids, different receptors, or heparin.62–69
In contrast, adhesion is a cellular process that involves the
formation of specific multiprotein complexes built by cell
adhesion molecules or receptors, ECM proteins, and cyto-
plasmic plaque or peripheral membrane proteins.106
It has been commonly reported that binding of
vitronectin to integrin receptors stimulates angiogenic activ-
ity in cells.107–110 However, in our experiments, non-
AMD-risk-associated VTN_rs704:C slightly reduced migra-
tion compared with control or VTN_rs704:T. Moreover, both
isoforms inhibited tube formation by HUVECs. This again
could be partially explained by the above-discussed antag-
onistic effect of PAI-1.98–105 Several studies have reported
an inhibition of cell migration105,111–113 and tube forma-
tion112,114 by PAI-1, due to blocking integrin or uroki-
nase receptor binding to vitronectin. Furthermore, Yi and
colleagues115 reported that the presence of vitronectin
sustains the antiangiogenic activity of several ECM or blood
proteins, such as osteonectin, or angiostatin, thus ascribing
an indirect antiangiogenic function to vitronectin. Notably,
non-AMD-risk-associated VTN_rs704:C showed a stronger
impairment of migration and tube formation than AMD-
risk-associated VTN_rs704:T, which suggests that the two
vitronectin isoforms may exert different regulatory effects
on angiogenesis and consequently on choroidal neovascu-
larization.
Of note, there are limitations of this study. Due to
the main localization of extracellular vitronectin protein
in sub-RPE regions, in specific in Bruch’s membrane and
the retinal vasculature,14 our experiments were designed
to address the sub-RPE aspects of AMD pathology, and
the results should not be extrapolated to the subretinal
aspects without further research. Moreover, due to the
complex and multifactorial nature of AMD, a variety of other
cellular processes may contribute to disease development,
e.g. lipid metabolism, complement activation, or oxidative
stress responses (reviewed in Datta et al.116 and Mitchell et
al.117). The multifaceted character of vitronectin (reviewed
in Leavesley et al.,3 Preissner and Reuning,50 and Schvartz
et al.70)—for example, as a complement inhibitor118 or as a
putative ligand of the apical RPE-localized integrin receptor
which facilitates neural retinal adhesion119—might allow its
involvement in all of these processes. Additional investiga-
tions on functional consequences of rs704 in these pathways
and especially subretinal disease aspects are thus required
to completely resolve the contribution of vitronectin to
AMD pathogenesis. Moreover, to address consequences of
the rs704-associated amino acid exchange on structural and
functional properties of vitronectin, we applied in vitro stud-
ies using recombinant vitronectin. This system benefits from
high reproducibility and low background (e.g., without the
impact of different genetic backgrounds or growth factors
with similar functions), enabling the detection of even small
alterations between the different vitronectin isoforms. The
in vivo situation in the retina, a highly specified, multilay-
ered tissue of different cell types affected by nutrient supply,
growth factors, external and internal stressors, and many
additional physiological factors, is surely more complex,
requiring caution in the interpretation of the data obtained.
Vitronectin functionality (and putative differences between
the two isoforms) might be affected or compensated by other
matricellular proteins, growth factors, or cytokines. Interest-
ingly, despite the involvement of vitronectin in a variety of
essential processes such as wound healing, tissue reorga-
nization, angiogenesis, or matrix remodeling (reviewed in
Leavesley et al.3), vitronectin-deficient mice show normal
development120 but disturbances in their reaction to tissue
injury.121 It was concluded that vitronectin is not required
for normal development but plays a role in the early events
of thrombogenesis and tissue repair121 (reviewed in Leaves-
ley et al.3). Connecting these findings to AMD pathogenesis,
vitronectin may not exert a major role in retinal integrity
until the emergence of disturbances in retinal homeosta-
sis caused by age-related changes, such as accumulation
of metabolic debris by RPE cells and Bruch’s membrane,
neuronal cell loss and degeneration, or alterations in the
ocular blood flow.122,123
Taken together, this study reveals effects of the AMD-risk-
associated rs704 polymorphism on the expression, process-
ing, and functionality of vitronectin, including its capacity
to regulate AMD-related processes. This may point to an
involvement of rs704 and vitronectin in AMD pathogenesis.
Nonetheless, the data do not exclude (additional) pathogenic
effects of other variants of the associated genetic locus
requiring further scrutiny to consider functional aspects of
all genes and variants involved at this locus.
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